ERAS-0015 pan-RAS-IN-2 (no INN/generic name assigned) Updated Jul 13
ERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.
- Phase 1 data shows best-in-class potential, 62% unconfirmed ORR in 2L+ KRAS G12X NSCLC and 57% in pancreatic cancer at RDE, numerically exceeding Revolution Medicines' RMC-6236 on cross-trial comparison
- Strong analyst consensus: 14 Buy/Strong Buy, 3 Hold, 0 Sell; mean price target $21 (7% upside from $17.90) with targets ranging up to $30
- Merck (MRK) collaboration validating, Keytruda combination study underway with Merck supplying pembrolizumab at no cost
- Securities class action lawsuit filed alleging misleading statements about preclinical comparisons to RMC-6236 between Jan 2025 and Apr 2026, lead-plaintiff deadline August 10, 2026
- Revolution Medicines has accused Erasca of patent infringement and trade secret misappropriation regarding ERAS-0015, creating significant IP overhang
- Stock crashed ~48% in April 2026 after disclosure of a patient death in the Phase 1 trial, safety concerns remain with early-stage data